LEVOFLOXACIN: BENEFIT-RISK RATIO


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses pharmacological properties and safety of the use of levofloxacin-fluoroquinolone, whose consumption in the world is constantly increasing. The reason for the increase in the use of levofloxacin is its more favorable benefit-risk ratio compared to many other fluoroquinolones, as evidenced by the results of not only clinical, but also widely conducted pharmacoepidemiological studies. The risk of developing serious adverse reactions with levofloxacin is generally lower than with other fluoroquinolones, and it can be significantly reduced by the rational use of the drug, which implies taking into account risk factors for the development of certain adverse reactions in a particular patient. To reduce the cost of treatment with levofloxacin, it is advisable to use its effective generics.

Full Text

Restricted Access

About the authors

E. A Ushkalova

FSAEI HE “Peoples' Friendship University of Russia"

Department of General and Clinical Pharmacology Moscow

S. K Zyryanov

FSAEI HE “Peoples' Friendship University of Russia"

Email: seiguei_kensarin@hotbox.ru
MD, Head of the Department of General and Clinical Pharmacology Moscow

References

  1. IMS Health National Sales Perspective (NSP), Y2014. Source File: NSP_2015-896 FQ AC 2014.
  2. Torres A., Liapikou A. Levofloxacin for the treatment of respiratory tract infections. Expert Opin. Pharmacother. 2012;13(8):1203-12.
  3. Noel G.J. A review of levofloxacin for the treatment of bacterial infections. Clin. Med. Ther. 2009;1:433-58.
  4. Lode H. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am. J. Med. 2010;123(4 Suppl.):S26-38.
  5. Salvo F., Polimeni G., Cutroneo P.M., Leone R., Confortic A., Moretti U., Motola D., Tuccori M., Caputi A.P. Allergic reactions to oral drugs: a case/ non-case study from an Italian spontaneous reporting database (GIF). Pharmacol. Res. 2008;58:202-7.
  6. Stahlmann R., Lode H.M. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin. Drug Saf. 2013;12(4):497-505.
  7. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 1999;28(2):352-64.
  8. Stahlmann R., Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193-209.
  9. Яковлев С.В. Место фторхинолонов в лечении бактериальных инфекций. Лечащий врач. 2008;2:59.
  10. Liu H.H. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33:353-69.
  11. Blanca-Lopez N., Andreu I., Torres Jaén M.J. Hypersensitivity reactions to quinolones. Curr. Opin. Allergy Clin. Immunol. 2011;11:285-91.
  12. Doha I., Barrionuevo E., Blanca-LopezN., Torres M.J., Fernandez T.D., Mayorga C., Canto G., Blanca M. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J. Investig. Allergol. Clin. Immunol. 2014;24(3):143-53.
  13. Sachs B., Riegel S., Seebeck J., Beier R., Schichler D., Barger A., Merk H.F, Erdmann S. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf. 2006;29(11):1087-100.
  14. Carbon C. Effets indésirables de la lévofloxacine: données des études cliniques et de la pharmacovigilance. Therapie. 2001;56:35-40.
  15. Van Bambeke F., Tulkens P.M. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009; 32 (5):359-78.
  16. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. J. Antimicrob. Chemother. 2011;66(7):1431-46.
  17. Ho C.C., Chen Y.C., Hu F.C., Yu C.J., Yang P.C., Luh K.T Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin. Infect. Dis. 2009;48:1526-33.
  18. Kalita J., Misra U.K., Prasad S., Bhoi S.K. Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial. J. Antimicrob. Chemother. 2014;69(8):2246-51.
  19. Guis S., Jouglard J., Kozak-Ribbens G., Figarella-Branger D., Vanuxem D., Pellissier J.F., Cozzone P.J. Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment. J. Rheumatol. 2001;28:1405-406.
  20. Korzets A., Gafter U., Dicker D., Herman M., Ori Y. Levofloxacin and rhabdomyolysis in a renal transplant patient. Nephrol. Dial. Transplant. 2006;21:3304-305.
  21. Sawant R.D. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can. J. Clin. Pharmacol. 2009;16:e7839.
  22. Baril L., Maisonobe T., Jasson-Molinier M., Haroche J., Bricaire F., Caumes E. Acute rhabdomyolysis during treatment with ofloxacin-a case report. Clin. Infect. Dis. 1999;29:1598-99.
  23. Jones S.C., Sorbello A., Boucher R.M. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011; 34(10):839-47.
  24. Forsythe C.T., Ernst M.E. Do fluoroquinolones commonly cause arthropathy in children? CJEM. 2007;9(6):459-62.
  25. Yee C.L., Duffy C., Gerbino P.G., Stryker S., Noel G.J. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr. Infect. Dis. J. 2002;21(6):525-29.
  26. Kaguelidou F., Turner M.A., Choonara I., Jacqz-Aigrain E. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr. Infect. Dis. J. 2011;30(2):e29-37.
  27. Schaad U.B. Will fluoroquinolones ever be recommended for common infections in children? Pediatr. Infect. Dis. J. 2007;26:865-67.
  28. Khaliq Y., Zhanel G.G. Fluoroquinolone6associated tendinopathy: a critical review of the literature. Clin. Infect. Dis. 2003;36:1404-10.
  29. Stephenson A.L., Wu W., Cortes D., Rochon P.A. Tendon Injury and Fluoroquinolone Use: A Systematic Review. Drug Saf. 2013; 36(9):709-21.
  30. Bidell M.R., Lodise T.P. Fluoroquino-lone2Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk? Pharmacotherapy. 2016;36(6):679-93.
  31. Arabyat R.M., Raisch D.W., McKoy J.M., Bennett C.L. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Expert Opin. Drug Saf. 2015;14(11):1653-60.
  32. Mehlhorn A.J., Brown D.A. Safety concerns with fluoroquinolones. Ann. Pharmacother. 2007;41(11):1859-66.
  33. van der Linden P.D., Sturkenboom M.C., Herings R.M., Leufkens H.M., Rowlands S., Stricker B.H. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch. Intern. Med. 2003;163:1801-807.
  34. Perry A.C., Prpa B., Rouse M.S., Piper K.E., Hanssen A.D., Steckelberg J.M., Patel R. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clin. Orthop. Relat. Res. 2003(414):95-100.
  35. Hall M.M., Finnoff J.T., Smith J. Musculoskeletal Complications of Fluoroquinolones: Guidelines and Precautions for Usage in the Athletic Population. PM R. 2011;3(2):132-42.
  36. Owens R.C. Jr, Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 2005;41(Suppl 2):S144-57.
  37. Fenichel R.R., Malik M., Antzelevitch C., Sanguinetti M., Roden D.M., Priori S.G., Ruskin J.N., Lipicky R.J. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. 2004;15(4):475-95.
  38. Lapi F., Wilchesky M., Kezouh A., Benisty J.I., Ernst P., Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin. Infect. Dis. 2012;55(11):1457-65.
  39. Zipes O.P., Camm A.J., Borggrefe M., et al; American College of Cardiology/American Heart Association Task Force.; European Society of Cardiology Committee for Practice Guidelines.; European Heart Rhythm Association and the Heart Rhythm Society. ACC/AHA/ ESC 2006guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur. Heart. J. 2006;27(17):2099-140.
  40. Kervezee L., Gotta V., Stevens J., Birkhoff W., Kamerling I., Danhof M., Meijer JH., Burggraaf J. Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration. CPT Pharmacometrics Syst. Pharmacol. 2016;5(9): 466-74.
  41. Graumlich J.F., Habis S., Avelino R.R., Salverson S.M., Gaddamanugu M., Jamma K., Aldag J.C. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy. 2005;25:1296-302.
  42. Park-Wyllie L.Y., Juurlink D.N., Kopp A., Shah B.R., Stukel T.A., Stumpo C., Dresser L., Low D.E., Mamdani M.M. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med. 2006;354:1352-61.
  43. Aspinall S.L., Good C.B., Jiang R., McCarren M., Dong D., Cunningham F.E. Severe dysglycemia with the fluoroquinolones: a class effect? Clin. Infect. Dis. 2009;49:402-8.
  44. Shehab N., Patel P.R., Srinivasan A., Budnitz D.S. Emergency department visits for antibiotic-associated adverse events. Clin. Infect. Dis. 2008;47:735-43.
  45. Rafat C., Debrix I., Hertig A. Levofloxacin for the treatment of pyelonephritis. Expert Opin Pharmacother. 2013;14(9):1241-53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies